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Abstract
Cisplatin is an essential chemotherapeutic agent in the treatment of many pediatric 
cancers. Unfortunately, cisplatin- induced hearing loss (CIHL) is a common, clini-
cally significant side effect with life- long ramifications, particularly for young chil-
dren. ACCL05C1 and ACCL0431 are two recently completed Children’s Oncology 
Group studies focused on the measurement and prevention of CIHL. The purpose of 
this paper was to gain insights from ACCL05C1 and ACCL0431, the first published 
cooperative group studies dedicated solely to CIHL, to inform the design of future 
pediatric otoprotection trials. Use of otoprotective agents is an attractive strategy for 
preventing CIHL, but their successful development must overcome a unique constel-
lation of methodological challenges related to translating preclinical research into 
clinical trials that are feasible, evaluate practical interventions, and limit risk. Issues 
particularly important for children include use of appropriate methods for hearing 
assessment and CIHL severity grading, and use of trial designs that are well- informed 
by preclinical models and suitable for relatively small sample sizes. Increasing inter-
est has made available new funding opportunities for expanding this urgently needed 
research.
K E Y W O R D S
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1 |  INTRODUCTION
Cisplatin is an essential chemotherapeutic agent in the treat-
ment of neuroblastoma, osteosarcoma, hepatoblastoma, germ 
cell tumors, medulloblastoma, and other pediatric cancers.1 
Unfortunately, cisplatin commonly causes sensorineural 
hearing loss that is bilateral, irreversible, and may progress 
over time.2 Cisplatin- induced hearing loss (CIHL) affects all 
ages. However, in children, especially very young children, 
it is particularly debilitating because hearing loss leads to 
impaired language acquisition, difficulty with learning and 
psychological development, and subsequent reduction in 
social functioning that will affect them for the remainder of 
their lives.3,4 Long- term studies of pediatric cancer survivors 
demonstrate that CIHL results in lower educational perfor-
mance, increased need for special education services, higher 
unemployment and nonindependent living, and poorer child- 
reported quality of life compared with controls.5-7 Depending 
on the cumulative dose and the dosing schedule, as many as 
75% of children with CIHL qualify for hearing aids or hear-
ing assistance.3,4,8 However, survivors with hearing aids still 
experience abnormal hearing, tinnitus, poor speech discrimi-
nation in noisy environments, social hardships, and substan-
tial expense.9,10
Because of these serious consequences, there is increas-
ing interest in identifying effective strategies for preventing 
CIHL. Historically, preventing CIHL has been limited to cis-
platin dose reduction or deletion, with or without substitution 
by its somewhat less ototoxic analog, carboplatin. However, 
cisplatin dose modifications are protocol specific and vari-
able.11,12 Further, reducing cisplatin dose intensity may jeop-
ardize treatment efficacy, and carboplatin is not uniformly 
equally effective.13 Dose reductions for CIHL are typically 
triggered after significant hearing loss has occurred, which is 
particularly important as hearing loss may worsen after con-
tinued exposure and completion of cisplatin.14 An alternative 
approach to preventing CIHL is use of otoprotective agents. 
Conceptually, a successful otoprotective agent would pro-
tect hearing without compromising chemotherapy efficacy. 
A recent systematic review evaluated multiple potential oto-
protectants including amifostine, glutathione, calcium, and 
magnesium, but none demonstrated efficacy in randomized 
clinical trials.15
The Children’s Oncology Group (COG) Cancer Control 
and Supportive Care Committee develops studies to reduce 
treatment- related toxicity among children with cancer.16 The 
COG recently completed two complementary studies address-
ing CIHL: ACCL05C1, an observational study to compare 
alternative methods for measuring CIHL;17 and ACCL0431, 
a randomized trial to evaluate sodium thiosulfate (STS) for 
prevention of CIHL.18 To our knowledge, these are the first 
published cooperative oncology group trials focused solely 
on CIHL. Given the importance and challenging nature of 
otoprotection research, the purpose of this paper was to de-
scribe issues that emerged from conducting these two studies 
(ACCL05C1 and ACCL0431) to inform the optimal design 
of future clinical trials evaluating agents for the prevention 
of CIHL.
2 |  CHALLENGES IN 
PREVENTING CIHL
Research methodology for evaluating new agents to prevent 
CIHL is fraught with challenges. These include identifying 
otoprotective agents that do not interfere with the anticancer 
effects of the chemotherapy and are safe for patients; utiliz-
ing appropriate preclinical models that optimize translation 
of the agent into human trials; and designing pediatric clini-
cal trials that can be conducted with reasonable sample sizes, 
are expected to accrue satisfactorily and are practical.
2.1 | Mechanisms and modifiers of CIHL
The pathophysiology of CIHL must be considered in de-
signing otoprotection studies. Factors associated with CIHL 
include age <5 years at time of treatment,19,20 cumulative 
cisplatin dose, duration of cisplatin infusion,21 cranial irradi-
ation,8,22,23 concomitant exposure to loop diuretics and ami-
noglycosides,4,24,25 and underlying genetic susceptibility.26-29 
Carboplatin also can cause hearing loss, especially at high 
doses or in very young children.30
Mechanisms underlying development of CIHL are com-
plex, and knowledge about them is evolving. In brief, cis-
platin crosses the blood- labyrinth barrier to gain access to 
cochlear tissues.31 Whereas the primary mechanism of cis-
platin’s anticancer activity is disruption of DNA replication 
and repair,32,33 CIHL is due principally to generation of re-
active oxygen species that induce mitochondrial damage and 
apoptosis of the cochlear outer hair cells.34-36 Pools of protec-
tive natural antioxidants such as glutathione are depleted.37 
Cisplatin also appears to damage the stria vascularis and re-
parative stem cells of the inner ear,38 resulting in increased 
cochlear uptake of cisplatin in the face of compromised cel-
lular rescue. Further delineation of the effects of ototoxic 
and otoprotective agents on the supporting cells, neurons, 
and central auditory pathways is needed to clarify mecha-
nisms beyond cochlear hair cell loss and to inform targeted 
interventions.39
2.2 | Preclinical models for identifying 
otoprotective agents
Guinea pig, rat, hamster, and gerbil models have been used 
for screening agents for cisplatin otoprotection. Species- 
specific differences in organ tolerance require various 
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cisplatin doses, schedules, and routes of administration. 
Recently, the zebrafish has emerged as a novel model 
for this purpose.40 Agents showing otoprotection must be 
screened for potential interference with cisplatin chemo-
therapy effects. This may be performed using in vitro can-
cer cell cytotoxicity assays, but generally requires tumor 
xenograft studies using nude mouse models. Thus, preclin-
ical research for otoprotective agents is complex in that a 
single animal model cannot be used for both otoprotection 
and tumor protection screening.
The goal should be a close integration of preclinical re-
search with the anticipated clinical trial. Specifically, the pre-
clinical model should incorporate physiologically relevant 
doses of both the otoprotectant and cisplatin, deliver these 
agents by the same schedule and route as planned in the clin-
ical trial, and screen for tumor protection using appropriate 
pediatric cancers. If applicable, screening for tumor protec-
tion should include other chemotherapeutic agents that may 
be included in the planned cisplatin regimen.
3 |  ISSUES IN CLINICAL TRIAL 
DESIGN AND CONDUCT
For agents demonstrating preclinical activity, a clinical trial 
is the essential translational step for confirming otoprotec-
tion and lack of tumor protection in humans, and for deter-
mining the side effect profile and burden of administration. 
Considerations important in designing an otoprotection 
clinical trial include the endpoints of interest, outcome as-
sessment, patient cohort characteristics, sample size, and 
the agent’s mode of delivery. Additionally, the trial must be 
T A B L E  1  Hearing assessments used for ototoxicity monitoring
Test Test description Age range Research applications
Pure tone 
audiometry
• Behavioral measurement of hearing thresholds in 
decibels (dB) for the speech frequency range 
(250-8000 Hz).
• Testing requires participation and cooperation of the 
subject.
• Assessment methods for young children include 
visual reinforcement audiometry (VRA) and 
conditioned play audiometry.
8 mo and older Standard method for hearing measure-
ment, detection of ototoxic damage and 
identification of communicatively 
significant hearing loss.
Extended high 
frequency 
audiometry
• Behavioral measurement of hearing thresholds in 
decibels (dB) for frequencies above the speech range.
• Test frequencies include 9000 Hz up to 20 000 Hz.
• Testing requires participation and cooperation of the 
subject.
• Not available at all institutions.
4- 5 y and older Provides a more sensitive and earlier 
signal of ototoxic damage because 
ototoxicity initially occurs at the highest 
audible frequencies.
Otoacoustic 
emissions (OAEs)
• Objective measurement of cochlear outer hair cell 
function.
• Does not require active subject participation.
• In the presence of normal middle ear function, loss of 
OAEs suggests outer hair cell damage but additional 
testing is needed to quantify change in hearing 
sensitivity.
• Available at most institutions.
Any age Typically provides a more sensitive and 
earlier signal of ototoxic damage. 
Available at most institutions.
Auditory brainstem 
response (ABR/
BAER)
• Objective measurement of neural responses to sound 
stimuli (auditory evoked potentials).
• For ototoxicity monitoring, tone burst stimuli are 
used to estimate hearing thresholds when behavioral 
audiometry is not possible due to age, development, 
or medical condition.
• The subject must be sleeping or lying completely still 
during testing.
• Useful for very young, medically debilitated or 
otherwise uncooperative patient (who may be 
sedated).
Any age Standard method for hearing measure-
ment, ototoxicity detection, and 
identification of communicatively 
significant hearing loss when behavioral 
testing is not possible.
Tympanometry • Objective measurement of middle ear pressure and 
function.
• Used to determine middle ear status.
Any age Necessary for valid interpretation of 
OAEs and to identify conductive middle 
ear pathology.
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practical and likely to accrue participants in a timely fash-
ion, a frequent challenge in pediatric supportive oncology 
research.41
3.1 | Ototoxicity assessment
For clinical trials where prevention or reduction in cisplatin- 
induced ototoxicity is the primary endpoint, a measure is 
needed that is valid, reliable, and sensitive to clinically rel-
evant change. Feasibility for clinical use, suitability for chil-
dren of varying ages and degrees of illness, and high inter- rater 
reliability are important characteristics. Ototoxicity is usu-
ally assessed as hearing loss. Although rarely assessed, clini-
cally significant tinnitus often accompanies CIHL, especially 
among older adolescents and young adults.10,42 The stand-
ard dictionary for reporting and grading severity of adverse 
events on National Cancer Institute (NCI)- sponsored clini-
cal trials is the Common Terminology Criteria for Adverse 
Event Reporting (CTCAE).43 These grading criteria, which 
are intended to identify harm that requires clinical action (eg, 
cisplatin dose modification), may not be sufficiently sensi-
tive as an endpoint in a toxicity reduction trial. A clinical 
trial for an otoprotectant must be able to capture mild, but 
functionally important, CIHL, particularly in young children.
In clinical trials, audiologic evaluations are the stan-
dard hearing assessment for older children and adolescents 
(Table 1). In younger children, temporary conductive hearing 
losses can frequently occur during therapy and may be con-
fused with ototoxicity.44 Very young, sick, or developmentally 
limited children may not be able to complete a full evalua-
tion, hindering accurate hearing assessment. Alternative test-
ing modalities, such as auditory brainstem response (ABR), 
may be needed postoperatively, early in treatment, or in very 
young children. However, switching assessment modalities 
between baseline and subsequent time points renders com-
parison for interval change more challenging.
Variation among measures of hearing loss hinders compar-
isons across published clinical trials.44,45 More than 8 differ-
ent criteria have been used to capture and assign hearing loss 
severity in pediatric cancer trials.46 In 2007, COG initiated 
ACCL05C1, a prospective observational cohort study of chil-
dren receiving cisplatin whose primary aim was to compare 
several hearing loss criteria in wide use at the time of study 
development, specifically, the American Speech- Language 
Hearing Association (ASHA),47 Brock,48 and the CTCAE 
v 3.0 criteria.49 Because raw, individual audiologic results 
were submitted for central review, it was possible to include 
the more recent SIOP- Boston Scale, which was developed in 
2012 through international consensus to address limitations 
posed by the other hearing loss criteria.50 The comparative 
analysis demonstrated that the SIOP- Boston Scale detected 
ototoxicity earlier than the other three measures, resulted in 
the highest percentage of evaluable audiograms, and had an 
acceptable false- positive rate. This scale offers advantages 
that include not requiring a baseline assessment for compar-
ison; being sensitive to CIHL; and aligning with functional 
patient outcomes.50,51
A key finding from ACCL05C1 was that central audiol-
ogy review proved feasible in the cooperative group setting, 
as data from 1436 assessments conducted at 53 participating 
institutions were successfully submitted to the COG coor-
dinating center. Central review improved standardization of 
grading compared to institutional reporting and provided the 
opportunity to re- grade severity by the newer SIOP- Boston 
Scale.
3.2 | Cohort selection and trial feasibility
ACCL0431 was a COG trial designed as a proof- of- concept 
study to determine whether STS prevented CIHL in chil-
dren.18 The cohort selection was intentionally broad to facili-
tate patient recruitment, but created challenges in interpreting 
the results of the trial. Participants were 1- 18 years old and 
newly diagnosed with any cancer for which a cumulative 
dose of cisplatin ≥200 mg/m2 was planned. The principal 
diagnoses were germ cell tumor, hepatoblastoma, medul-
loblastoma, neuroblastoma, and osteosarcoma. The ration-
ale for including multiple tumor types was the assumption 
that diagnosis would not impact the risk of ototoxicity after 
adjusting for age, cisplatin regimen, and cranial irradiation. 
Participants were randomized to receive or not receive STS 
in addition to their disease- specific cisplatin- containing regi-
men. The primary endpoint was development of hearing loss, 
as defined by ASHA criteria, at 4 weeks following the final 
dose of cisplatin. Event- free survival (EFS) and overall sur-
vival (OS) were monitored as secondary endpoints. Because 
the sample size was determined in relation to the primary aim 
of hearing loss, ACCL0431 had power to detect only large 
differences in survival.
There were 125 eligible, randomized participants 
(Table 2). Among the 104 participants evaluable for the pri-
mary endpoint, the incidence of CIHL among those who re-
ceived STS was approximately half that of controls (Table 3). 
Among all 125 participants in aggregate, there was no sta-
tistically significant difference in EFS and OS at a median 
follow- up of 3.5 years (Table 3). However, a difference in OS 
that approached statistical significance favoring the control 
group prompted an unplanned, post hoc analysis stratified by 
extent of disease (localized vs disseminated). In that analysis, 
participants with localized disease demonstrated no survival 
difference by randomized group, whereas those with dissem-
inated disease demonstrated significantly lower EFS and OS 
if they received STS (Table 3). Progressive cancer accounted 
for all but one death. Taken together, these results were defin-
itive for the primary outcome of otoprotection but concerning 
for the possibility of systemic tumor protection by STS.
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The design of ACCL0431 afforded both strengths and 
limitations. Use of a heterogeneous cohort simultaneously 
facilitated accrual and provided definitive evidence of oto-
protection by STS. On the other hand, heterogeneity of the 
cohort limited the ability to determine the effect of STS on 
survival because of the small sample size within each diagno-
sis type (Table 2), particularly when further divided by extent 
of disease.
A consideration from the ACCL0431 experience is that 
heterogeneous diagnoses precluded the ability to consider 
detailed prognostic information as potential factors in sur-
vival. Although cancer types, extent of disease, and age of 
participants appeared to be balanced in the two randomiza-
tion groups on ACCL0431, it is possible that within cancer 
types there was an imbalance of unmeasured biological fea-
tures that influence outcome and would be incorporated in 
a more sophisticated risk- group assignment. Thus, designing 
a trial to evaluate for an otoprotection signal alone may not 
provide all the information needed to translate unanticipated 
results into practice if a heterogeneous cohort is enrolled.
A study design limiting the population to a single cancer 
type treated with a protocol- specified chemotherapy regi-
men would allow cisplatin dose modifications, deletions, and 
delays to be captured. Yet, many pediatric cancers are rare. 
Therefore, a conventional noninferiority trial design evalu-
ating an otoprotectant and its potential for tumor protection 
within a single cancer type would require large sample sizes 
to exclude small but meaningful decrements in event- free or 
overall survival. One such study, a European trial randomiz-
ing standard risk hepatoblastoma patients to STS or observa-
tion (SIOPEL- 6), has recently been completed.52,53
Future trial designs employing methods to assess 
co- primary endpoints, for example, otoprotection and 
progression- free survival, should be used by building on the 
lessons of these early efforts and by following FDA guidance 
for multiple endpoints in clinical trials.54 Such designs will 
require appropriate planning, including sufficiently large 
sample sizes to examine joint effects in the most promising 
otoprotection treatment strategies.
3.3 | Delivery of the otoprotection agent
ACCL0431 addressed the concern about the systemic de-
livery of both cisplatin and STS using a strategy of time 
separation of cisplatin and STS. Based on preclinical stud-
ies, a 6- hour interval between completion of cisplatin and 
administration of STS was specified to ensure preservation 
of cisplatin anticancer activity.55,56 An alternative strategy 
for avoiding interference with systemic chemotherapy is 
T A B L E  2  Cohort characteristics of the ACCL0431 study18
Control 
n (%)
STS 
n (%)
Age (y)
<5 22 (34) 22 (36)
5- 9 13 (20) 7 (11)
10- 14 14 (22) 16 (26)
15- 18 15 (23) 16 (26)
Cancer type
Germ cell tumor 16 (25) 16 (26)
Hepatoblastoma 5 (8) 2 (3)
Medulloblastoma or CNS 
PNET
14 (22) 12 (20)
Neuroblastoma 12 (19) 14 (23)
Osteosarcoma 15 (23) 14 (23)
Other 2 (3) 3 (5)
Extent of diseasea
Localized 38 (59) 39 (64)
Disseminated 26 (41) 21 (34)
Unknown 0 1 (2)
aDetermined post hoc.
T A B L E  3  Major results of the ACCL0431 study18
Control group % (95% 
Confidence Interval)
Sodium thiosulfate Group % (95% 
Confidence Interval) P
Risk ratio (95% 
Confidence Interval) P
Hearing Lossa 56.4 (16.6, 43.3) 28.6 (42.3, 69.7) .00022b 0.31c (0.13- 0.73) .0036d
Survivale
Event- Free 64 (50, 74) 54 (40, 66) - 1.30f (0.75, 2.26) .36g
Overall 87 (76, 93) 70 (56, 80) - 2.03f (0.93, 4.44) .07g
aAs defined by the American Speech- Language Hearing Association (ASHA).
bChi- square test of proportions.
cOdds ratio.
dLogistic regression test.
eAt 3 y, all eligible participants combined.
fRelative hazard ratio.
gLog- rank test.
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utilization of chemoprotectants whose activity is anatomi-
cally restricted through their pharmacokinetic properties or 
via loco- regional administration. An example of the former 
is mesna, a systemically delivered uroprotectant to prevent 
hemorrhagic cystitis that is activated only upon excretion via 
the kidney.57,58
In concept, loco- regional delivery of an otoprotectant by 
intratympanic injection is associated with minimal systemic 
absorption and positions the otoprotectant in contact with the 
round window through which it diffuses into the cochlea.59 
A loco- regional approach affords an efficient accrual design 
and statistical evaluation approach through randomization 
“by ear” (ie, in a single patient use of one ear for the inter-
vention and the contralateral ear for the control). However, 
challenges also exist for the intratympanic approach, which 
include the potential need for procedural sedation, availabil-
ity of pediatric otolaryngologists, need for coordination of 
medical and surgical teams, and potential effects on hearing 
from the intratympanic agent and vehicle.60,61
4 |  CONCLUSION
With ACCL0431 providing proof- of- principle that CIHL can 
be prevented, interest in preventing CIHL is growing and 
new otoprotection agents are in early stages of development. 
What major insights from ACCL05C1 and ACCL0431 can 
inform optimal design of future otoprotection trials? From 
ACCL05C1, we recommend: (1) use of uniform, internation-
ally accepted ototoxicity criteria that are optimal for children 
(eg, the SIOP- Boston Scale); and (2) use of central review 
of raw audiologic data to improve accuracy, reduce bias, 
and allow use of multiple ototoxicity criteria for comparison 
between randomized groups. From ACCL0431, we recom-
mend: (1) use of a study cohort that is well- characterized for 
disease characteristics and treatment variables to reduce the 
impact of confounders on both ototoxicity and survival out-
comes; and (2) ensuring sufficient statistical methods, power, 
and sample size to assess multiple primary endpoints and 
interactions.
In addition, insights reinforced by the COG experience 
include ensuring that the preclinical studies and clinical 
trials are exceptionally well integrated with regard to dose, 
schedule, route, and administration of the otoprotectant and 
cisplatin, as well as the cancers being studied. Ideally, iden-
tification of otoprotectants that are mechanistically distinct 
from the chemotherapy would minimize concern for inhi-
bition of chemotherapy effects. Alternatively, loco- regional 
administration of otoprotectants by intratympanic injection 
offers similar theoretical advantages. Clearly, more stringent 
requirements for the study population may require longer 
recruitment periods and may limit feasibility and generaliz-
ability. Thus, a balance of the study cohort and the specific 
endpoints is a consideration for each trial design. Published 
final results of SIOPEL- 6, which used an alternative study 
design, will contribute to our understanding of optimal ap-
proaches for pediatric otoprotection trials, as well as the 
emerging discussion about a potential clinical role for STS 
and the potential generalizability of its use to prevent ototox-
icity beyond hepatoblastoma.53 As well, there may be a need 
for future discussion about what might constitute an appro-
priate control arm in the future randomized clinical trials of 
new otoprotectants.
Regardless of study design, other aspects of ototoxic-
ity, including tinnitus, reduced speech comprehension in 
noisy environments, and impact of hearing loss on daily 
function and quality of life, are important outcomes. We 
recommend including a more comprehensive set of mea-
sures for these in the future clinical trials, particularly for 
older children, adolescents, and young adults who can pro-
vide patient- reported outcomes. Additional studies may 
further elucidate novel agents and approaches to reduce or 
T A B L E  4  NIH funding opportunity announcements
Funding opportunity announcement Number Link
PPQ- 6: How can mouse or other preclinical 
models be used to study how standard of care 
and investigational therapies affect normal 
tissue and lead to adverse events later in life?
PAR- 16- 217 Research Answers to NCI’s Pediatric Provocative 
Questions (R21) https://grants.nih.gov/grants/guide/
pa-files/PAR-16-217.html
PPQ- 7: How can prediction models be devel-
oped and used to identify patients at highest 
risk of treatment- related complications?
PAR- 16- 218 NCI Research Answers to NCI’s Pediatric 
Provocative Questions (R01) https://grants.nih.gov/
grants/guide/pa-files/PAR-16-218.html
National Cancer Institute (NCI) Mechanisms of 
Cancer and Treatment- related Symptoms and 
Toxicities (R21)
PA- 16- 258 https://grants.nih.gov/grants/guide/pa-files/
PA-16-258.html
National Institutes of Health (NIH) Serious 
Adverse Drug Reaction Research (R01/R21)
PAR- 16- 275 and PAR- 16- 274 https://grants.nih.gov/grants/guide/pa-files/
PAR-16-275.html and https://grants.nih.gov/grants/
guide/pa-files/PAR-16-274.html
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prevent ototoxicity. The National Institutes of Health (NIH) 
released several funding announcements (Table 4) specifi-
cally to highlight the need to develop preclinical models to 
study the effects of anticancer agents and regimens on nor-
mal tissue and on the development of late adverse effects, 
and to identify patients at highest risk of treatment- related 
complications.
The successes of ACCL0431 and ACCL05C1 are but the 
beginning of a new era of otoprotection research for children 
facing the prospect of developing CIHL. These studies have 
contributed to a paradigm shift in pediatric oncology that no 
longer considers CIHL as acceptable and demands continued 
research to expand the available options for effective otopro-
tection and refine the ways in which these are applied.
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